<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38472">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01853722</url>
  </required_header>
  <id_info>
    <org_study_id>13-150-0002</org_study_id>
    <nct_id>NCT01853722</nct_id>
  </id_info>
  <brief_title>A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers</brief_title>
  <official_title>A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deacon Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deacon Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof-of-concept study evaluates the clinical efficacy and safety of DCN01 in prepping
      of the periocular region.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change from baseline in periocular region bacterial load</measure>
    <time_frame>Baseline to 10 min post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of periocular regions with a reduction from baseline in bacterial load.</measure>
    <time_frame>Baseline to 10 min post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (reported, elicited, observed)</measure>
    <time_frame>Post dose and up to 2 weeks after (Day 1-14)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Ocular Infection</condition>
  <arm_group>
    <arm_group_label>DCN01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Unisol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCN01</intervention_name>
    <description>Three serial applications per periocular region.</description>
    <arm_group_label>DCN01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unisol</intervention_name>
    <description>Three serial applications per periocular region.</description>
    <arm_group_label>Unisol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have given a written, informed consent

          -  Be willing and able to follow all instructions

          -  A negative urine pregnancy test if female of childbearing potential

        Exclusion Criteria:

          -  Known sensitivities to study medication or its components

          -  Any signs of an active infection

          -  Use of disallowed products during the period indicated prior to the  enrollment or
             during the study

          -  Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a
             positive pregnancy test

          -  Have a condition or a situation which, in the Investigator's opinion, may put the
             subject at increased risk, confound study data, or interfere significantly with the
             subject's study participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sunita Saigal</last_name>
    <phone>978-685-8900</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gail L Torkildsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 9, 2013</lastchanged_date>
  <firstreceived_date>May 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DCN01</keyword>
  <keyword>Ocular Surgical Preparation</keyword>
  <keyword>Prophylaxis against infection</keyword>
  <keyword>Pre-operative prep</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eye Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
